CLINICAL EFFICACY AND SAFETY OF AND A-2 ANTAGONIST EPROSARTAN IN PATIENTS WITH MILD AND MODERATE HYPERTENSION. RESULTS OF A MULTICENTER TRIAL
Abstract
Clinical efficacy and safety of and A-2 antagonist eprosartan in patients with mild and moderate hypertension. Results of a multicenter trial.
About the Authors
L. I. Olbinskaya
Московская Медицинская Академия им. И.М.Сеченова
Russian Federation
Russian Federation
T. B. Andrushicina
Московская Медицинская Академия им. И.М.Сеченова
Russian Federation
Russian Federation
References
1. Kannel W.B. Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevatoin to cardiovascular risk profile// Am. Heart J. - 1999, 138: S203-204.
2. He J., Whelton O. Elevated systolic blood pressure as risk factor for cardiovascular and renal disease// J. Hypertension - 1999, Vol. 17 , Suppl. 2, S7-13.
3. Shusterman N.H. Safety and efficacy of eprosartan, a new angiotensin II receptor blocker// Am. Heart J. - 1999, Vol 138 : N3, Part2, S238-245.
4. Hedner T. J . Management of hypertension: the advent of a new angiotensin II receptor antagonist// J. Hyрertension - 1999; 17(Suppl.2):S21-25.
5. Weber M. Clinical efficacy of eprosartan// Pharmacotherapy - 1999; 19, S95-101.
6. Brooks D P, Eliot H., Ruffolo R R. Pharmacology of eprosartan, an angiotensin II receptor antagonist: Exploring hypotheses from clinical data// Am. Heart J. - 1999, Vol 138 : N3, Part 2, S246- 251
7. Gavras I., Gavras H. Safety and Tolerability of eprosartan// Pharmacotherapy - 1999; 19: S102-107.
Review
For citations:
Olbinskaya L.I., Andrushicina T.B. CLINICAL EFFICACY AND SAFETY OF AND A-2 ANTAGONIST EPROSARTAN IN PATIENTS WITH MILD AND MODERATE HYPERTENSION. RESULTS OF A MULTICENTER TRIAL. Russian Journal of Cardiology. 2001;(3):43-46. (In Russ.)
Views:
253
Email this article 